Abstract. The author presents adopted in different regions of the world standards of multimodal treatment of patients with locally advanced gastric cancer, and the results of large multicenter randomized studies on which they are based. It is shown that adjuvant chemotherapy with S-1 and XELOX improves long-term outcomes. At the same time, the additional use of paclitaxel, the combination of the scheme FOLFIRI with docetaxel and cisplatin failed to improve the survival rate. Existing data do not allow to make unambiguous conclusion about the benefits of adjuvant chemoradiotherapy. Promising areas of researches are an use of neoadjuvant therapy, targeted therapies, the search for biomarkers to predict the prognosis and the efficacy of adjuvant therapy.
Key words: gastric cancer, multimodal treatment, D2 gastrectomy, adjuvant chemotherapy, adjuvant chemoradiation therapy, preoperative therapy, neoadjuvant therapy.
A. Tsyb Medical Radiological Research Center of National Medical Research Radiological Center, Obninsk
Skoropad V.Yu. ― D. Med. Sc., Leading Researcher, Department of Abdominal Oncology of the A. Tsyb Medical Radiological Research Center of National Medical Research Radiological Center
10 Zhukov Str., Obninsk, Russian Federation, 249036, tel. (48439) 93165, e-mail: email@example.com